Fda grants Therachon company apraglutide treatment for orphan drug for short bowel syndrome
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
short bowel syndrome (SBS) is caused by extensive intestinal removal caused by chronic inflammatory bowel disease (IBD), acute events (such as intestinal infarction), or congenital abnormalitiesrecently, TherachonCompany(http:// announcedthat the U.SFood
and Drug(http://Regulatory Authority
(http://has granted apraglutide treatment of short intestine syndrome (SBS) orphan drugIn the European Union, the European Medicines Agency (EMA) has previously granted apraglutide the status of orphan drugs for SBSa pruptide
apraglutide (FE 203799) is a new generation ofsynthetic(http:// GLP-2 analogues that have been extensively pre-clinically characterized and optimized apraglutide has successfully completed a phase I single-dose/multiple-dose clinical study of Health (http:// volunteers, demonstrating good pharmacokinetic characteristics, half-life of 30 hours, and achieving an easy-to-use weekly administration currently, apraglutide is evaluating the efficacy and safety of the treatment of SBS in 2 Phase II clinical studies
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
